- Home
- PCRX vs CTO Comparison
PCRX vs CTO Comparison
Compare PCRX & CTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PCRX | CTO |
|---|---|---|
| Founded | 2006 | 1902 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 776.3M |
| IPO Year | 2010 | 1995 |
Fundamental Metrics
Financial Performance| Metric | PCRX | CTO |
|---|---|---|
| Price | $25.19 | $20.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $30.00 | $24.60 |
| AVG Volume (30 Days) | ★ 424.0K | 308.3K |
| Earning Date | 11-05-2026 | 10-27-2026 |
| Dividend Yield | N/A | ★ 7.42% |
| EPS Growth | 107.44 | ★ 122.86 |
| EPS | ★ 0.19 | 0.13 |
| Revenue | ★ $541,533,000.00 | $149,545,000.00 |
| Revenue This Year | $3.85 | $18.22 |
| Revenue Next Year | $4.69 | $9.81 |
| P/E Ratio | ★ $134.42 | $159.08 |
| Revenue Growth | ★ 26.04 | 20.10 |
| 52 Week Low | $18.80 | $15.07 |
| 52 Week High | $27.66 | $22.71 |
Technical Indicators
Market Signals| Indicator | PCRX | CTO |
|---|---|---|
| Relative Strength Index (RSI) | 51.01 | 38.27 |
| Support Level | $22.13 | $19.87 |
| Resistance Level | $27.03 | $20.83 |
| Average True Range (ATR) | 0.84 | 0.35 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 68.38 | 32.63 |
Price Performance
Historical ComparisonAbout PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties in diversified markets in the United States. The company operates in four primary business segments: Income properties, management services, commercial loans and investments, and real estate operations. It derives maximum revenue from Income Properties.